Once-daily combinations of a basal insulin with a GLP-1 RA offer two agents with complementary mechanisms of action for better glycemic control in type 2 diabetes mellitus, while reducing risks of hypoglycemia and weight gain, and allowing for simplification of the treatment regimen.
Unaccredited
Sonja Reichert, MD, MSc, CCFP
Stewart Harris, MD, MPH, FCFP, FACPM